Azacytidine Treatment for VEXAS Syndrome

por Raaijmakers, Marc H. G. P., Hermans, Maud, Aalbers, Anna, Rijken, Melissa, Dalm, Virgil A. S. H., van Daele, Paul, Valk, Peter J. M.
Publicado 2021

P634: EARLY-STAGE MEASURABLE RESIDUAL DISEASE DYNAMICS AND IGHV REPERTOIRE RECONSTITUTION DURING VENETOCLAX AND OBINUTUZUMAB TREATMENT IN CHRONIC LYMPHOCYTIC LEUKEMIA

por Hengeveld, Paul, Schilperoord-Vermeulen, Joyce, van der Klift, Michèle, Dubois, Julie, Martijn Kolijn, Pieter, Kavelaars, François, Rijken, Melissa, Dobber, Johan, Nasserinejad, Kazem, Kersting, Sabina, Westerweel, Peter, Kater, Arnon, Langerak, Anton, Levin, Mark-David
Publicado 2023

DNA vs cDNA FLT3-ITD allelic ratio and length measurements in adult acute myeloid leukemia

por Cucchi, David G. J., Vonk, Christian M., Rijken, Melissa, Kavelaars, François G., Merle, Pauline A., Verhoef, Elvira, Venniker-Punt, Bianca, Kwidama, Zinia J., Gradowska, Patrycja, Löwenberg, Bob, Janssen, Jeroen J. W. M., Cloos, Jacqueline, Valk, Peter J. M.
Publicado 2021

Prognostic Value of FLT3-Internal Tandem Duplication Residual Disease in Acute Myeloid Leukemia

por Grob, Tim, Sanders, Mathijs A., Vonk, Christian M., Kavelaars, Franҫois G., Rijken, Melissa, Hanekamp, Diana W., Gradowska, Patrycja L., Cloos, Jacqueline, Fløisand, Yngvar, van Marwijk Kooy, Marinus, Manz, Markus G., Ossenkoppele, Gert J., Tick, Lidwine W., Havelange, Violaine, Löwenberg, Bob, Jongen-Lavrencic, Mojca, Valk, Peter J.M.
Publicado 2023

High-throughput Proteomics Identifies THEMIS2 as Independent Biomarker of Treatment-free Survival in Untreated CLL

por Hengeveld, Paul J., Kolijn, P. Martijn, Demmers, Jeroen A.A., Doff, Wouter, Dubois, Julie M.N., Rijken, Melissa, Assmann, Jorn L.J.C., van der Straten, Lina, Boiten, Henk Jan, Gussinklo, Kirsten J., Valk, Peter J.M., Faber, Laura M., Westerweel, Peter E., Kater, Arnon P., Levin, Mark-David, Langerak, Anton W.
Publicado 2023